ME - 23andMe Holding Co. Stock Price, Fair Value and News

0.51USD+0.05 (+10.87%)Delayed as of 29 Apr 2024, 02:15 pm ET

Market Summary

USD0.51+0.05

Delayedas of 29 Apr 2024, 02:15 pm

10.87%

ME Stock Price

View Fullscreen

ME RSI Chart

ME Valuation

Market Cap

222.2M

Price/Earnings (Trailing)

-0.43

Price/Sales (Trailing)

0.9

EV/EBITDA

0.04

Price/Free Cashflow

-1.2

ME Price/Sales (Trailing)

ME Profitability

Operating Margin

45.30%

EBT Margin

-210.72%

Return on Equity

-138.38%

Return on Assets

-85.82%

Free Cashflow Yield

-83.52%

ME Fundamentals

ME Revenue

Revenue (TTM)

248.0M

Rev. Growth (Yr)

-33.15%

Rev. Growth (Qtr)

-10.5%

ME Earnings

Earnings (TTM)

-522.0M

Earnings Growth (Yr)

-202.28%

Earnings Growth (Qtr)

-269.31%

Breaking Down ME Revenue

52 Week Range

0.53

(Low)(High)

Last 7 days

-2.1%

Last 30 days

-7.8%

Last 90 days

-37.3%

How does ME drawdown profile look like?

ME Financial Health

Current Ratio

2.15

ME Investor Care

Shares Dilution (1Y)

5.05%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	299.5M	295.8M	270.2M	248.0M
2022	271.9M	277.2M	297.6M	307.7M
2021	243.9M	255.1M	258.5M	259.9M
2020	305.5M	290.1M	274.7M	259.3M
2019	440.9M	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 23andMe Holding Co.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	hibbs kathy l	sold	-18,148	0.4708	-38,548	chief administrative officer
Apr 18, 2024	hibbs kathy l	acquired	16,190	0.42	38,548	chief administrative officer
Apr 04, 2024	hibbs kathy l	acquired	16,190	0.42	38,548	chief administrative officer
Apr 04, 2024	hibbs kathy l	sold	-19,281	0.5002	-38,548	chief administrative officer
Mar 21, 2024	hibbs kathy l	sold	-17,894	0.4642	-38,548	chief administrative officer
Mar 21, 2024	hibbs kathy l	acquired	16,190	0.42	38,548	chief administrative officer
Mar 07, 2024	hibbs kathy l	acquired	16,190	0.42	38,548	chief administrative officer
Mar 07, 2024	hibbs kathy l	sold	-20,430	0.53	-38,548	chief administrative officer
Feb 22, 2024	hibbs kathy l	acquired	16,190	0.42	38,548	chief administrative officer
Feb 22, 2024	hibbs kathy l	sold	-23,325	0.6051	-38,548	chief administrative officer

Which funds bought or sold ME recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-10.18	-427,672	469,107	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-49.26	-23,000	10,000	-%
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	unchanged	-	-23,335	32,541	-%
Apr 25, 2024	Allworth Financial LP	unchanged	-	-763	1,064	-%
Apr 25, 2024	Lindbrook Capital, LLC	unchanged	-	-114	160	-%
Apr 24, 2024	BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC	unchanged	-	-191	266	-%
Apr 24, 2024	Cambridge Investment Research Advisors, Inc.	sold off	-100	-72,000	-	-%
Apr 24, 2024	Root Financial Partners, LLC	unchanged	-	-5,104	7,117	-%
Apr 23, 2024	Gradient Investments LLC	sold off	-100	-64.00	-	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-60.14	-16,000	5,000	-%

Are Funds Buying or Selling ME?

Are funds buying ME calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ME

No. of Funds

Unveiling 23andMe Holding Co.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 17, 2024	abeec 2.0, llc	23.9%	98,633,827	SC 13D/A
Feb 13, 2024	vanguard group inc	7.24%	22,554,104	SC 13G/A
Feb 09, 2024	gsk plc	11.2%	39,660,487	SC 13D/A
Jan 26, 2024	blackrock inc.	7.2%	22,467,761	SC 13G
Dec 12, 2022	fmr llc	-	0	SC 13G/A
Nov 04, 2022	gsk plc	13.2%	39,660,487	SC 13D

Recent SEC filings of 23andMe Holding Co.

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	4	Insider Trading
Apr 18, 2024	8-K	Current Report
Apr 17, 2024	SC 13D/A	13D - Major Acquisition
Apr 05, 2024	4	Insider Trading
Mar 29, 2024	8-K	Current Report
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	S-8	Employee Benefits Plan
Mar 11, 2024	4	Insider Trading
Mar 07, 2024	144	Notice of Insider Sale Intent
Feb 23, 2024	4	Insider Trading

Peers (Alternatives to 23andMe Holding Co.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	182.5B	23.7B	-0.93%	6.50%	41.46	7.69	-8.94%	-35.72%
IDXX	41.5B	3.7B	-7.44%	3.05%	49.1	11.33	8.72%	24.44%
A	40.3B	6.7B	-6.59%	3.31%	32.64	5.99	-2.81%	-6.58%
DGX	14.9B	9.3B	2.40%	-4.82%	17.61	1.6	-3.29%	6.68%
MEDP	12.3B	2.0B	-1.91%	100.24%	39.22	6.24	25.57%	21.62%
CRL	11.8B	4.1B	-15.01%	24.62%	24.77	2.85	3.86%	-2.39%
NTRA	11.1B	1.1B	1.32%	82.46%	-25.45	10.22	31.99%	20.63%
EXAS	10.7B	2.5B	-11.98%	-7.20%	-52.35	4.28	19.93%	67.26%
MID-CAP
NEOG	2.6B	929.2M	-21.41%	-29.07%	1.7K	2.83	28.93%	111.61%
GH	2.1B	563.9M	-3.40%	-19.97%	-4.4	3.74	25.45%	26.76%
SMALL-CAP
CDNA	391.4M	280.3M	-28.23%	-2.96%	-2.06	1.4	-12.89%	-148.37%
ACRS	85.1M	31.2M	-5.56%	-86.21%	-0.96	2.72	5.03%	-1.81%
APDN	74.2M	9.0M	916.28%	337.00%	-10.27	8.25	-53.31%	2.21%
AWH	41.1M	9.2M	-2.92%	-32.04%	-2.46	4.49	11.85%	44.12%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

23andMe Holding Co. News

Latest updates

23andMe Holding Co. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q1
Revenue	-10.5%	44,747,000	49,999,000	60,864,000	92,377,000	66,940,000	75,659,000	64,513,000	100,559,000	56,891,000	55,204,000	59,239,000	88,582,000	55,477,000	51,804,000	48,057,000	-	-
Cost Of Revenue	-12.2%	24,811,000	28,270,000	30,184,000	52,395,000	36,189,000	37,386,000	39,023,000	53,502,000	29,628,000	27,276,000	28,542,000	44,053,000	30,089,000	27,209,000	25,563,000	-	-
Gross Profit	-8.3%	19,936,000	21,729,000	30,680,000	39,982,000	30,751,000	38,273,000	25,490,000	47,057,000	27,263,000	27,928,000	30,697,000	44,529,000	25,388,000	24,595,000	22,494,000	-	-
Operating Expenses	198.6%	301,146,000	100,860,000	139,944,000	109,256,000	127,851,000	106,314,000	115,086,000	116,511,500	123,964,000	74,375,000	72,247,000	2,673,527	70,531,000	60,849,000	59,216,000	-	-
S&GA Expenses	51.0%	27,683,000	18,328,000	22,658,000	21,779,000	39,879,000	24,835,000	33,434,000	29,351,500	41,979,000	13,588,000	15,419,000	11,955,000	12,258,000	8,329,000	10,655,000	-	-
R&D Expenses	-23.6%	41,720,000	54,588,000	62,329,000	60,719,000	57,270,000	52,598,000	52,009,000	50,324,000	50,298,000	44,523,000	44,232,000	45,596,500	41,684,000	38,205,000	34,370,000	-	-
EBITDA Margin	-79.3%	-1.94	-1.08	-0.96	-0.91	-0.91	-0.96	-0.87	-0.72	-0.76	-0.59	-0.65	-0.68	-	-	-	-	-
Interest Expenses	-13.9%	3,230,000	3,752,000	4,307,000	4,368,500	3,671,000	1,392,000	245,000	64,500	76,000	92,000	44,000	59,500	53,000	69,000	74,000	-	-
Income Taxes	-47.2%	19,000	36,000	-	-887,500	-613,000	-1,271,000	254,000	32,000	-3,512,000	-	-	-	-	-	-	-	-
Earnings Before Taxes	-269.5%	-277,957,000	-75,234,000	-104,624,000	-64,731,500	-92,574,000	-67,336,000	-89,786,000	-69,512,000	-92,908,000	-16,524,000	-42,026,000	-	-44,645,000	-	-	-	-
EBT Margin	-68.9%	-2.11	-1.25	-1.11	-1.05	-1.04	-1.07	-0.97	-0.81	-0.84	-0.66	-0.72	-0.75	-0.97	-0.91	-0.86	-0.82	-
Net Income	-269.3%	-277,976,000	-75,270,000	-104,624,000	-64,098,000	-91,961,000	-66,065,000	-89,532,000	-69,544,000	-89,396,000	-16,524,000	-42,026,000	23,295,969	-44,645,000	-36,191,000	-35,770,000	-	-
Net Income Margin	-69.3%	-2.10	-1.24	-1.10	-1.04	-1.03	-1.06	-0.96	-0.80	-0.48	-0.31	-0.39	-0.38	-0.97	-0.91	-0.86	-0.82	-0.42
Free Cashflow	78.8%	-12,196,000	-57,415,000	-69,774,000	-46,155,000	24,636,000	-73,265,000	-74,654,000	-36,753,000	-25,208,000	-63,636,000	-45,199,000	-1,200,825	28,200,000	-29,602,000	-36,444,000	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q1
Assets	-24.1%	608	801	871	943	1,025	1,041	1,062	1,152	1,226	903	947	452	510	457	405
Current Assets	4.0%	310	298	360	425	509	506	520	602	670	769	815	314	1.00	-	253
Cash Equivalents	-5.4%	242	256	314	387	441	419	488	562	595	709	778	291	297	185	216
Inventory	4.6%	16.00	15.00	12.00	10.00	12.00	14.00	11.00	11.00	17.00	18.00	15.00	6.00	-	-	14.00
Net PPE	-7.7%	30.00	33.00	36.00	39.00	41.00	44.00	47.00	50.00	52.00	54.00	58.00	61.00	-	-	78.00
Goodwill	-56.5%	153	352	352	352	352	352	352	352	352	-	-	-	-	-	-
Liabilities	31.3%	231	176	196	229	274	221	208	236	265	244	284	210	88.00	179	270
Current Liabilities	41.9%	144	102	119	149	200	145	128	153	180	114	123	122	-	1.00	139
Shareholder's Equity	-39.7%	377	625	675	714	751	819	854	916	961	660	663	5.00	5.00	0.00	0.00
Retained Earnings	-16.5%	-1,964	-1,686	-1,611	-1,506	-1,442	-1,350	-1,284	-1,194	-1,125	-1,035	-1,019	-977	-48.60	-0.01	-793
Additional Paid-In Capital	1.3%	2,341	2,311	2,287	2,221	2,194	2,168	2,138	2,110	2,086	1,695	1,682	382	54.00	0.00	173
Shares Outstanding	0.9%	473	469	462	452	450	448	447	362	427	407	168	100	95.00	95.00	88.00

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q1
Cashflow From Operations	78.9%	-12,061	-57,119	-69,355	-44,961	25,545	-72,934	-73,040	-35,205	-24,598	-62,492	-44,533	-1,006	28,433	-29,514	-32,905	-	-
Share Based Compensation	11.0%	26,357	23,741	51,100	22,250	34,338	28,967	30,462	20,460	17,409	10,427	9,637	51,203	14,995	10,866	11,361	-	-
Cashflow From Investing	27.4%	-2,012	-2,773	-2,695	-3,288	-3,066	-2,051	-2,900	-3,197	-95,824	-7,729	-1,387	-789	-744	-1,055	-3,948	-	-
Cashflow From Financing	-93.4%	105	1,593	-114	2,606	-11.00	5,649	1,533	5,522	5,780	1,333	533,369	300	83,891	35,561	1,026	-	-

ME Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue (includes related party revenue of nil and $13,068 for the three months ended December 31, 2023 and 2022, respectively, and $11,753 and $36,258 for the nine months ended December 31, 2023 and 2022, respectively)	$ 44,747,000	$ 66,940,000	$ 155,610,000	$ 207,112,000
Cost of revenue (includes related party cost of nil and $231 for the three months ended December 31, 2023 and 2022, respectively, and $295 and $(279) for the nine months ended December 31, 2023 and 2022, respectively)	24,811,000	36,189,000	83,265,000	112,598,000
Gross profit	19,936,000	30,751,000	72,345,000	94,514,000
Operating expenses:
Research and development (includes related party expenses of $2,781 and $3,251 for the three months ended December 31, 2023 and 2022, respectively, and $10,989 and $9,517 for the nine months ended December 31, 2023 and 2022, respectively)	41,720,000	57,270,000	158,637,000	161,877,000
Sales and marketing	27,683,000	39,879,000	68,669,000	98,148,000
General and administrative	31,446,000	30,702,000	107,476,000	89,226,000
Restructuring and other charges	1,497,000	0	8,368,000	0
Goodwill impairment	198,800,000	0	198,800,000	0
Total operating expenses	301,146,000	127,851,000	541,950,000	349,251,000
Loss from operations	(281,210,000)	(97,100,000)	(469,605,000)	(254,737,000)
Other income (expense):
Interest income, net	3,230,000	3,671,000	11,289,000	5,307,000
Other income (expense), net	23,000	855,000	501,000	(267,000)
Loss before income taxes	(277,957,000)	(92,574,000)	(457,815,000)	(249,697,000)
Provision for (benefit from) income taxes	19,000	(613,000)	55,000	(2,139,000)
Net loss	(277,976,000)	(91,961,000)	(457,870,000)	(247,558,000)
Other comprehensive income (loss), net of tax	0	(1,943,000)	620,000	(490,000)
Total comprehensive loss	$ (277,976,000)	$ (93,904,000)	$ (457,250,000)	$ (248,048,000)
Net loss per share of Class A and Class B common stock attributable to common stockholders:
Net loss per share attributable to common stockholders, basic (usd per share)	$ (0.58)	$ (0.20)	$ (0.97)	$ (0.55)
Net loss per share attributable to common stockholders, diluted (usd per share)	$ (0.58)	$ (0.20)	$ (0.97)	$ (0.55)
Weighted-average shares used to compute net loss per share:
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (shares)	480,809,546	453,407,202	472,683,220	449,949,829
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (shares)	480,809,546	453,407,202	472,683,220	449,949,829

ME Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Mar. 31, 2023
Current assets:
Cash and cash equivalents	$ 242,418	$ 386,849
Restricted cash	1,399	1,399
Accounts receivable, net	18,154	1,897
Inventories	15,666	10,247
Deferred cost of revenue	12,222	5,376
Prepaid expenses and other current assets	20,100	19,224
Total current assets	309,959	424,992
Property and equipment, net	30,270	38,608
Operating lease right-of-use assets	50,738	56,078
Restricted cash, noncurrent	6,974	6,974
Internal-use software, net	19,827	15,661
Intangible assets, net	35,234	45,520
Goodwill	152,944	351,744
Other assets	2,265	3,021
Total assets	608,211	942,598
Current liabilities:
Accounts payable (includes related party amounts of $7,064 and $3,186, respectively)	13,166	12,924
Accrued expenses and other current liabilities (includes related party amounts of $8,780 and $8,738, respectively)	42,124	66,430
Deferred revenue (includes related party amounts of $5,000 and $11,753, respectively)	80,468	62,521
Operating lease liabilities	8,381	7,541
Total current liabilities	144,139	149,416
Deferred revenue, noncurrent (includes related party amounts of $15,000 and nil, respectively)	15,000	0
Operating lease liabilities, noncurrent	70,441	77,763
Other liabilities	1,443	1,480
Total liabilities	231,023	228,659
Commitments and contingencies (Note 11)
Stockholders’ equity
Preferred stock - par value $0.0001, 10,000,000 shares authorized as of December 31, 2023 and March 31, 2023; zero shares issued and outstanding as of December 31, 2023 and March 31, 2023	0	0
Common stock, par value $0.0001 - Class A shares, 1,140,000,000 shares authorized, 315,073,368 and 293,020,474 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively; Class B shares, 350,000,000 shares authorized, 167,480,278 and 168,179,488 shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively	48	46
Additional paid-in capital	2,341,394	2,220,897
Accumulated other comprehensive loss	0	(620)
Accumulated deficit	(1,964,254)	(1,506,384)
Total stockholders’ equity	377,188	713,939
Total liabilities and stockholders’ equity	$ 608,211	$ 942,598

About 23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.

CEO	Ms. Anne Wojcicki
WEBSITE	23andme.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	758

23andMe Holding Co. Frequently Asked Questions

What is the ticker symbol for 23andMe Holding Co.? What does ME stand for in stocks?

ME is the stock ticker symbol of 23andMe Holding Co.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 23andMe Holding Co. (ME)?

As of Fri Apr 26 2024, market cap of 23andMe Holding Co. is 222.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ME stock?

You can check ME's fair value in chart for subscribers.

What is the fair value of ME stock?

You can check ME's fair value in chart for subscribers. The fair value of 23andMe Holding Co. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 23andMe Holding Co. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ME so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 23andMe Holding Co. a good stock to buy?

The fair value guage provides a quick view whether ME is over valued or under valued. Whether 23andMe Holding Co. is cheap or expensive depends on the assumptions which impact 23andMe Holding Co.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ME.

What is 23andMe Holding Co.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, ME's PE ratio (Price to Earnings) is -0.43 and Price to Sales (PS) ratio is 0.9. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ME PE ratio will change depending on the future growth rate expectations of investors.